Insider transactions
Catherine T. Doherty, who serves as Executive Vice President at Quest Diagnostics (NYSE: DGX), recorded two stock disposals in early March 2026, according to a Form 4 filing with the Securities and Exchange Commission.
On March 3, 2026, Doherty sold 632 shares of common stock at $207.73 per share, producing proceeds of $131,285. The previous day, March 2, 2026, she disposed of 648 shares at $204.86 per share for a total of $132,749. The filing specifies the March 2 sale was made to satisfy tax obligations arising from the vesting of restricted share units.
The Form 4 indicates that, after these transactions, Doherty directly owns 67,122 shares of Quest Diagnostics. In addition, the filing notes an indirect holding of 4,502 shares through the company 401(k) plan.
Plan-based execution
The sale reported on March 3 was carried out pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. The filings do not add further operational commentary beyond the details of the dispositions and the ownership levels reported.
Context - share performance and recent company developments
The timing of the trades coincides with Quest Diagnostics shares trading near their 52-week high of $213.50 and with year-to-date gains of approximately 21%.
Corporate updates filed and announced by the company around the same period include fourth-quarter 2025 financial results that exceeded analyst expectations. Quest Diagnostics reported earnings per share of $2.42 versus a forecast of $2.36, and revenue of $2.81 billion against an anticipated $2.75 billion.
On the strategic front, Quest Diagnostics named Benjamin Beauvalot senior vice president, chief strategy and M&A officer. The company described Beauvalot as having over 20 years of experience in business strategy and mergers and acquisitions.
Quest Diagnostics also rolled out the Quest AI Companion, an AI-powered feature integrated into the MyQuest mobile app. The company says the tool uses Google’s Gemini models to assist users in interpreting lab results.
Key points
- Two disposals by an EVP totaled $263, (1) $131,285 on March 3 and (2) $132,749 on March 2; the latter covered taxes on vested restricted share units.
- After the transactions, Doherty directly holds 67,122 shares and indirectly holds 4,502 shares through the 401(k) plan.
- Transactions occurred while DGX traded near a 52-week high and following a quarterly earnings beat and strategic product and personnel moves.
Risks and uncertainties
- The filings document insider sales but do not provide insight into future personal trading plans or company guidance - relevant to investors in healthcare equities and broader equity markets.
- While the March 2 sale was explicitly to cover tax obligations from vesting RSUs, the filing does not disclose other motivations for the March 3 sale under the 10b5-1 plan - a factor for market participants assessing insider activity.
- Corporate developments noted in filings - including executive appointments and product launches - are summarized without forward-looking detail on operational impact, which leaves uncertainty for analysts modeling future revenues in the diagnostics and healthcare services sectors.
Note: All transaction amounts, dates, ownership figures, accounting results, and product and personnel announcements are drawn from the company filings and disclosures referenced in this report.